4.64
-0.095(-2.01%)
Currency In USD
| Previous Close | 4.73 |
| Open | 4.88 |
| Day High | 4.93 |
| Day Low | 4.55 |
| 52-Week High | 13.5 |
| 52-Week Low | 2.28 |
| Volume | 74,702 |
| Average Volume | 169,305 |
| Market Cap | 43.13M |
| PE | -1.35 |
| EPS | -3.44 |
| Moving Average 50 Days | 5.49 |
| Moving Average 200 Days | 5.63 |
| Change | -0.1 |
If you invested $1000 in Clene Inc. (CLNN) since IPO date, it would be worth $23.77 as of February 21, 2026 at a share price of $4.635. Whereas If you bought $1000 worth of Clene Inc. (CLNN) shares 5 years ago, it would be worth $16.81 as of February 21, 2026 at a share price of $4.635.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
GlobeNewswire Inc.
Jan 12, 2026 1:30 PM GMT
The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are significantly associated with lower mortality risk, sup
Clene Announces Registered Direct Offering of Over $28 Million
GlobeNewswire Inc.
Jan 09, 2026 1:30 PM GMT
Oversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo CapitalInitial financing tranche of over $6 million, which we expect will provide c
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
GlobeNewswire Inc.
Dec 03, 2025 1:00 PM GMT
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8Biomarker improvements are strongly associated with longer survival, reinforcing CNM-Au8’s potential disease modifying ac